A method for assessing cardiac function suitable for incorporation into an implantable cardiac rhythm management device. By measuring daily exertion levels in accordance with the invention, an assessment of cardiac function can be made that has been found to correlate well with conventional clinical classifications. The invention also provides for assessing cardiac function in conjunction with different pacing schemes designed to treat heart failure and using the assessment to select the best such scheme for the patient.
|
0. 27. A method, comprising:
configuring a cardiac rhythm management device to measure a moving average over a specified averaging period of exertion levels attained by a patient during daily activities;
extracting maximal exertion levels from the moving averages of the exertion levels measured over a specified duration;
classifying the patient's cardiac functional status based upon the maximal exertion levels; and
performing a testing sequence in which different pacing schemes are tried for predetermined periods and a patient's functional status is assessed for each scheme tried.
7. A system for assessing a patent's cardiac functional status, comprising:
a sensor adapted to measure an exertion level; and
a processor, coupled to the sensor, the processor adapted to:
calculate a moving averaged exertion level from the measured exertion level over a specified averaging period;
extract a maximal exertion level from the moving averaged exertion levels calculated over a first duration, the first duration including a plurality of the specified averaging periods; and classify the patient's cardiac functional status based on the maximal exertion durations extracted over a second duration, the second duration including a plurality of the first durations.
1. A cardiac rhythm management device, comprising:
one or more sensing channels amplifiers for sensing atrial and ventricular cardiac depolarization signals, each channel including an electrode and a sense amplifier;
a pulse generator for delivering pacing pulses to the atrium and/or ventricle;
an exertion level sensor; and
a processor for controlling the delivery of pacing pulses in response to elapsed time intervals and detected depolarization signals in accordance with a programmed mode, wherein the processor is programmed to perform a method comprising:
measuring a moving average over a specified averaging period of exertion levels attained by the patient during daily activities;
extracting daily maximal exertion levels from the measured moving average exertion levels for a specified number of days; and
classifying the patient's cardiac functional status based upon the daily maximum daily maximal exertion levels.
17. A cardiac rhythm management device, comprising:
a first sensing channel adapted to sense a first cardiac signal;
a first pacing channel adapted to deliver pacing pulses to a first cardiac site;
a second sensing channel adapted to sense a second cardiac signal;
a second pacing channel adapted to deliver pacing pulses to a second cardiac site;
a first sensor adapted to measure a first exertion level;
a processor, coupled to the first and second sensing channels, the first and second pacing channels, and the first sensor, the processor adapted to:
calculate a moving average exertion level from the measured exertion level over a specified averaging period;
extract a maximal exertion level from the moving average exertion levels calculated over a first duration, the first duration including a plurality of the specified averaging periods;
classify the patient's cardiac functional status based on the maximal exertion durations extracted over a second duration, the second duration including a plurality of the first durations; and
control the delivery of the pacing pulses based on at least the first and second cardiac signals and a programmed pacing mode.
2. The device of
3. The device of
4. The device of
5. The device of
6. The device of
8. The system of
9. The system of
10. The system of
11. The system of
12. The system of
13. The system of
14. The system of
at least one sensing channel adapted to sense a cardiac signal;
at least one pacing channel adapted to deliver pacing pulses; and
wherein the processor is adapted to control the delivery of the pacing pulses based on the cardiac signal and one of a plurality of pacing schemes, each of the plurality of pacing schemes including a particular pacing mode and a plurality of timing parameters.
15. The system of
16. The system of
18. The device of
19. The device of
20. The device of
21. The device of
22. The device of
a third sensing channel adapted to sense a third cardiac signal;
a third pacing channel adapted to deliver pacing pulses to a third cardiac site; and
wherein the processor is adapted to control the delivery of the pacing pulses based on at least the first, second, and third cardiac signals, and the programmed pacing mode.
23. The device of
24. The device of
25. The device of
26. The device of
0. 28. The method of claim 27 wherein the exertion levels are measured by an accelerometer incorporated into the cardiac rhythm management device.
0. 29. The method of claim 27 wherein the exertion levels are measured by a minute ventilation sensor incorporated into the cardiac rhythm management device.
0. 30. The method of claim 27 wherein the steps are performed automatically at periodic times by an implantable device.
0. 31. The method of claim 27 further comprising transmitting measured and moving averaged exertion levels from the cardiac rhythm management device to an external programmer.
|
This patent application is a division of U.S. patent application Ser. No. 09/551,310, filed on Apr. 18, 2000, now issued as U.S. Pat. No. 6,473,646, the specification of which is incorporated herein by reference.
This invention pertains to systems and methods for delivering pacing and other therapies to treat cardiac conditions and for assessing the effectiveness of such therapies.
Congestive heart failure (CHF) is a clinical syndrome in which an abnormality of cardiac function causes cardiac output to fall below a level adequate to meet the metabolic demand of peripheral tissues. CHF can be due to a variety of etiologies with that due to ischemic heart disease being the most common. Symptoms of CHF in certain instances can be due to cardiac arrhythmias that are treatable with conventional bradycardia pacing. Some CHF patients suffer from some degree of AV block such that their cardiac output can be improved by synchronizing atrial and ventricular contractions with dual-chamber pacing (i.e., pacing both the atria and the ventricles) using a short programmed AV delay time. It has also been shown that some CHF patients suffer from intraventricular conduction defects (a.k.a. bundle branch blocks) such that their cardiac outputs can be increased by improving the synchronization of right and left ventricular contractions. Cardiac pacemakers have therefore been developed which provide pacing to both ventricles, termed biventricular pacing.
In CHF patients who are treated with pacing therapy (e.g., either a conventional pacemaker or a biventricillar pacemaker), it is desirable to select a pacing scheme that optimally improves the patient's condition. Examples of a pacing scheme include a particular pacing mode and parameter values related to that mode such as lower rate limit, AV delay time, and biventricular delay time. Pacing schemes are conventionally selected based upon a clinical assessment of the patient's condition. For example, EKG data may indicate a patient is likely to be benefited more with biventricular pacing than with conventional dual-chamber pacing. After being set initially, the pacing scheme can then be adjusted on a trial and error basis to a more optimum one based upon the patient's history and physical examination in subsequent office visits. This also allows the pacing scheme to be adjusted in accordance with any changes that occur in the patient's physical condition. This method of assessing a CHF patient's cardiac functional status can be a very subjective one, however, depending on the physician's perception of the patient's symptoms and physical disability. There is a need, therefore, for a method of assessing a CHF patient's functional status that is more accurate and reproducible than those currently practiced in order to select a pacing scheme. It is toward this objective that the present invention is primarily directed.
The present invention relates to a method for assessing the functional status of congestive heart failure patients that is particularly suitable for use in selecting optimal pacing schemes for those patients receiving pacing therapy. In accordance with the invention, maximal exertion levels of the patient are tracked with an implantable device while the patient goes about his or her daily activities. Such maximal exertion levels have been found to correlate well with other methods of classifying a patient's cardiac functional status. In one embodiment, the method is performed by measuring a moving average over a specified averaging period of exertion levels attained by the patient during daily activities. Daily maximal exertion levels are then extracted from the measured moving average exertion levels for a specified number of days, and the patient's cardiac functional status is classified based upon the daily maximum daily exertion levels. The exertion levels are measured by a sensor that measures a physiological variable related to exertion level such as an accelerometer or minute ventilation sensor.
The method may be incorporated in a cardiac pacemaker used to treat congestive heart failure where the functional status assessment is used to either automatically select an optimum pacing scheme or to aid the clinician in making the selection. In such a device, a processor for controlling the operation of the device is programmed to perform the method using data collected from an exertion level sensor. The daily maximal exertion levels are registered and stored by the device, and may then be transmitted to an external programmer. The processor may also be programmed to automatically adjust a pacing scheme of the device based upon the extracted maximal exertion levels obtained during a testing sequence in which different pacing schemes are tried.
Assessing the functional status of a heart failure patient is usually done with a comprehensive history and physical examination. The physician's perception of the patient's symptoms and physical disability is then used to classify the patient's status according to a classification system such as that put forth by the Criteria Committee of the New York Heart Association (NYHA). It has been found that measured maximum exertion levels of a patient during daily living are well correlated to such classifications. In accordance with the invention, a patient's cardiac functional status is classified based upon measurements of maximal exertion levels attained by the patient as the patient goes about normal activities during the day. The exertion level measurements are performed by an implantable device such as a pacemaker or a portable external device. In a particular embodiment, exertion level signals from, e.g., an accelerometer and/or minute ventilation sensor are automatically collected by an implantable device and moving averaged over a period from 30 seconds to 10 minutes, with the daily maximum moving average value being registered and stored. The daily maximum moving average value is then averaged over a specified time period (e.g., on a weekly, monthly, or semiannual basis) with the resulting average maximum exertion level also registered and stored. By gathering exertion level data while different therapies are being tried, an indication of the effectiveness of the therapy in treating the patient's condition can be obtained.
The preferred way of implementing the exertion level measurements is to employ the same type of exertion level sensor used to control rate-adaptive pacemakers. A rate-adaptive pacemaker varies the pacing rate in accordance with a measured physiological variable related to metabolic rate or exertion level. (See, e.g., U.S. Pat. No. 5,376,106 issued to Stahmann et al., the disclosure of which is hereby incorporated by reference). Measuring minute ventilation, which is the product of ventilation rate and tidal volume, estimates oxygen consumption which is related to exertion level. Another way of determining exertion level is by measuring body activity or motion with either an accelerometer or vibration sensor. The activity-sensing pacemaker uses a microphone-like sensor (e.g., an accelerometer) inside the pacemaker case that responds to mechanical vibrations of the body by producing electrical signals proportional to the patient's level of physical activity.
The present invention can be used to assess the effectiveness of any therapy used to treat congestive heart failure or otherwise improve a patient's cardiac functional status. In the embodiments described below, the invention is incorporated into the control unit of an implantable pacemaker and used to evaluate different pacing schemes. Examples of such schemes include a particular bradycardia pacing mode, a lower rate limit, parameters related to rate-adaptive pacing, a programmed atrio-ventricular delay for dual-chamber pacing, and an interventricular delay for biventricular pacing. As noted above, biventricular pacemakers are sometimes used in the treatment of congestive heart failure where pacing pulses are delivered to both ventricles by separate electrodes during a cardiac cycle. (See, e.g., U.S. Pat. Nos. 5,792,203 and 4,928,688 which are hereby incorporated by reference). In a biventricular pacemaker, the right and left ventricles are sensed through separate channels with either both ventricles or only the left ventricle being paced upon expiration of a selected lower rate interval without receipt of a right ventricular sense signal, where the lower rate interval starts with either a pacing event or receipt of a right ventricular sense signal. In the case of biventricular pacing, the ventricles may be paced simultaneously or one after the other separated by a selected delay interval. The pacemaker may also be operated in a ventricular triggered mode where one or both ventricles are paced within a latency period following a sense signal from the right ventricle. Such different pacing schemes may vary in their effectiveness for any given patient, and the present invention provides a way of ascertaining which scheme is best.
Shown in
Also shown interfaced to the microprocessor 10 are a number of interval timers 11 to be discussed below. These timers may either be discrete counters as shown or be implemented in software by the microprocessor executing programmed instructions in memory 12. A pacemaker is a device which paces one or more chambers based upon sensed events and the outputs of interval timers. In an atrial triggered pacemaker, timers for the following intervals are provided: lower rate interval (LRI) which defines the minimum rate at which the ventricles will be paced in the absence of spontaneous activity, atrioventricular delay interval (AVD) which defines the time delay between an atrial pulse or sense and the ensuing ventricular pace if no ventricular sense occurs in the interval, and atrial escape interval (AEI) which defines a minimum rate for atrial pacing in the case of an atrial paced mode. For biventricular pacing, an interval timer for the interventricular delay (IVD) is provided that defines the delay between the time the two ventricles are paced. The IVD, for example, can be set to zero to enable simultaneous pacing of the ventricles or can be set to a positive or negative value to enable sequential pacing of the two ventricles in the specified order and after the specified delay interval. Other interval timers are used to define refractory periods for the sensing channels during which time the channels are closed so that inputs are ignored.
In a particular embodiment of the invention, the method for assessing a patient's cardiac function as described above is implemented in the control unit of a pacemaker as illustrated in
If the automatic mode is not enabled, the exertion level information associated with different therapies is displayed to the clinician upon interrogation of the device and can be used to select the best therapy. The stored exertion level data also provides a long-term history of maximal exertion levels that are representative of a patient's capability to perform physical activities and general state of health. Such a history may be useful to the clinician in making treatment decisions or in diagnosis.
Therapies other than pacing schemes may also be tested and evaluated by the method described above in which exertion levels are measured while different therapies are tried. This may involve selectively turning on or turning off different device therapeutic features to provide optimum therapy or reconfiguring parameter settings. For example, an implantable drug delivery device capable of delivering different drug therapies to treat conditions affecting a patient's cardiac functional status may use the present method to select the best therapy. A device can also be programmed to activate an additional diagnostic monitoring operation when there is a change in the patient's status as reflected by measured exertion levels. Such diagnostic monitoring may be normally turned for resource conservation or because the patient is required to exercise in order for the test to be performed. For example, rate dependent bundle branch block can be detected by activating AV delay monitoring when the exertion level is above a certain threshold.
Although the invention has been described in conjunction with the foregoing specific embodiment, many alternatives, variations, and modifications will be apparent to those of ordinary stall in the art. Such alternatives, variations, and modifications are intended to fall within the scope of the following appended claims.
KenKnight, Bruce H., Sun, Weimin, Sanders, Richard S., Kadhiresan, Veerichetty
Patent | Priority | Assignee | Title |
Patent | Priority | Assignee | Title |
4928688, | Jan 23 1989 | MIROWSKI FAMILY VENTURES L L C | Method and apparatus for treating hemodynamic disfunction |
5376106, | Oct 18 1993 | Cardiac Pacemakers, Inc. | Multi-sensor blending in a rate responsive cardiac pacemaker |
5540727, | Nov 15 1994 | Cardiac Pacemakers, Inc. | Method and apparatus to automatically optimize the pacing mode and pacing cycle parameters of a dual chamber pacemaker |
5626622, | Sep 21 1994 | Pacesetter, Inc | Dual sensor rate responsive pacemaker |
5626662, | May 21 1994 | Hoechst Aktiengesellschaft | Fine division in the preparation of organic pigments |
5792203, | Aug 18 1997 | Intermedics Inc | Universal programmable cardiac stimulation device |
5891176, | Oct 25 1996 | Pacesetter, Inc.; Pacesetter, Inc | System and method for providing hemodynamically optimal pacing |
5978711, | Feb 23 1998 | Vivatron Medical, B.V. | Pacemaker system with improved learning capability for adapting rate response function |
6021351, | May 11 1998 | Cardiac Pacemakers, Inc | Method and apparatus for assessing patient well-being |
6044298, | Oct 13 1998 | Cardiac Pacemakers, Inc. | Optimization of pacing parameters based on measurement of integrated acoustic noise |
6129744, | Dec 04 1997 | VITATRON MEDICAL, B V | Cardiac treatment system and method for sensing and responding to heart failure |
6273856, | Oct 19 1999 | Cardiac Pacemakers, Inc. | Apparatus and methods for METS measurement by accelerometer and minute ventilation sensors |
6473646, | Apr 18 2000 | Cardiac Pacemakers, Inc | Method and apparatus for assessing cardiac functional status |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Oct 03 2007 | Cardiac Pacemakers, Inc. | (assignment on the face of the patent) | / |
Date | Maintenance Fee Events |
Dec 30 2011 | ASPN: Payor Number Assigned. |
Mar 06 2013 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
Mar 23 2017 | M1553: Payment of Maintenance Fee, 12th Year, Large Entity. |
Date | Maintenance Schedule |
Oct 11 2014 | 4 years fee payment window open |
Apr 11 2015 | 6 months grace period start (w surcharge) |
Oct 11 2015 | patent expiry (for year 4) |
Oct 11 2017 | 2 years to revive unintentionally abandoned end. (for year 4) |
Oct 11 2018 | 8 years fee payment window open |
Apr 11 2019 | 6 months grace period start (w surcharge) |
Oct 11 2019 | patent expiry (for year 8) |
Oct 11 2021 | 2 years to revive unintentionally abandoned end. (for year 8) |
Oct 11 2022 | 12 years fee payment window open |
Apr 11 2023 | 6 months grace period start (w surcharge) |
Oct 11 2023 | patent expiry (for year 12) |
Oct 11 2025 | 2 years to revive unintentionally abandoned end. (for year 12) |